Verona Pharma | MedPath

Verona Pharma to Present Comprehensive Analyses of Ohtuvayre in COPD at ATS 2025

16 days ago

• Verona Pharma will present ten posters at ATS 2025, including seven analyses from Phase 3 ENHANCE studies demonstrating Ohtuvayre's efficacy in diverse COPD patient populations. • Ohtuvayre (ensifentrine), a first-in-class dual PDE3 and PDE4 inhibitor, showed significant improvements in lung function and reduced exacerbation rates in patients with COPD, including those with comorbid conditions. • The analyses highlight Ohtuvayre's effectiveness as both monotherapy and in patients with comorbidities such as cardiac disorders and type 2 diabetes, representing the first novel inhaled mechanism for COPD treatment in over 20 years.

Verona Pharma's Ohtuvayre Shows Strong Launch in COPD Market

5 months ago

• Verona Pharma reports Ohtuvayre achieved approximately $36 million in net product sales for Q4 2024 and $42 million for the full year, marking a strong initial uptake. • Over 3,500 unique healthcare professionals prescribed Ohtuvayre to a broad COPD population, with over 16,000 prescriptions filled in 2024, indicating rapid adoption. • Verona Pharma is advancing its COPD program with a Phase 2b trial of ensifentrine combined with glycopyrrolate planned for Q3 2025, expanding treatment options. • The company's cash reserves are robust, with approximately $400 million in cash and cash equivalents as of December 31, 2024, supporting ongoing development.

Verona Pharma's Ohtuvayre™ (ensifentrine) Achieves $5.6 Million in Q3 Sales Amidst Pipeline Expansion

7 months ago

• Verona Pharma reported a successful launch of Ohtuvayre™ (ensifentrine) in the US, recording $5.6 million in net sales for Q3 2024, with October sales exceeding the Q3 total. • Over 2,200 healthcare professionals prescribed Ohtuvayre, filling more than 5,000 prescriptions across a broad spectrum of COPD patients within the first 12 weeks. • Verona Pharma has initiated two Phase 2 clinical trials, one evaluating a fixed-dose combination of nebulized ensifentrine with glycopyrrolate for COPD and another assessing nebulized ensifentrine in non-cystic fibrosis bronchiectasis (NCFBE). • Nuance Pharma, Verona's development partner in Greater China, has completed enrollment in a pivotal Phase 3 trial of ensifentrine for COPD, with results expected in 2025.

GSK's Depemokimab Shows Promise in Reducing Severe Asthma Exacerbations

9 months ago

• Depemokimab significantly reduced severe asthma attacks by 54% compared to placebo in Phase 3 trials, offering a potential new treatment option. • The ultra-long-acting biologic showed a 72% reduction in exacerbations requiring hospitalization or emergency department visits, highlighting its clinical impact. • Administered just twice yearly, depemokimab could improve treatment adherence and provide sustained suppression of type 2 inflammation in severe asthma. • These findings, presented at the European Respiratory Society International Conference, support regulatory filings for depemokimab globally.

Verona Pharma Launches Ohtuvayre for COPD and Advances Pipeline

9 months ago

• Verona Pharma's Ohtuvayre (ensifentrine) is now available in the U.S. for chronic obstructive pulmonary disease (COPD) maintenance treatment, marking a novel inhaled option. • The company plans to initiate Phase 2 trials for a fixed-dose combination of ensifentrine and glycopyrrolate, and for nebulized ensifentrine in non-cystic fibrosis bronchiectasis in Q3 2024. • Early launch data shows positive healthcare provider response, with over 100 HCPs prescribing Ohtuvayre shortly after launch, indicating strong initial interest. • Verona Pharma reports a strong cash position of over $400 million, supporting commercialization efforts and ongoing clinical development programs.

Verona Pharma's Ohtuvayre (ensifentrine) Receives FDA Approval for COPD Maintenance Treatment

a year ago

• The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults, marking a novel advancement. • Ohtuvayre is the first inhaled COPD treatment in over two decades with a new mechanism, acting as a dual inhibitor of PDE3 and PDE4 enzymes for bronchodilation and anti-inflammatory effects. • Clinical trials (ENHANCE-1 and ENHANCE-2) demonstrated significant improvements in lung function and reduced exacerbations, supporting the drug's efficacy and safety profile. • Verona Pharma plans to launch Ohtuvayre in Q3 2024, backed by substantial funding, aiming to address the unmet needs of millions suffering from daily COPD symptoms.

Ensifentrine Shows Promise in Improving Lung Function and COPD Symptoms

5 years ago

• A Phase 2b trial of ensifentrine demonstrated statistically significant improvements in lung function in COPD patients. • The study also met clinically relevant secondary endpoints, showing improvements in COPD symptoms. • Ensifentrine is a first-in-class, inhaled, dual inhibitor of phosphodiesterase 3 and 4, acting as both an anti-inflammatory and bronchodilator. • Verona Pharma anticipates an End-of-Phase 2 meeting with the FDA to discuss Phase 3 program design.